Skip to main content
. 2024 Jan 3;38:e00354. doi: 10.1016/j.plabm.2023.e00354

Table 2.

Cross-reactivity analysis.

Cross Reactivity Studies
sBCMA Concentration of 70.0 ng/mL
Drug Name Drug Concentration (% of total solution) Percent Cross -Reactivity Percent Recovery
Daratumumab 5% 3% 103%
10% −4% 96%



Isatuximab 5% 2% 101%
10% −4% 97%



Talquetamab 2% 1% 101%
5% 4% 105%
8% −1% 103%
10% 0.4 105%



Belantamab 1% −1875% 5%
5% −2477% 4%
10% −2168% 5%



AMG 701 2% −474% 18%
5% −923% 10%
8% −966% 10%
10% −998% 10%